EUVIMEDEUVIMED entdecken
Open Access

Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study

Julie E Oomens, Veerle van Gils, Stephanie J B Vos, Whitney M Freeze, Nancy N Maserejian, Gioacchino Curiale, Cai Gillis, Mercè Boada, Wiesje M van der Flier, Jakub Hort, Sterling C Johnson, Alberto Lleó und 38 weitere

JAMA Network Open · 22.01.2025 · 8 (1) · e2455571

DOI: 10.1001/jamanetworkopen.2024.55571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 22.01.2025. Verfasst von Julie E Oomens und 49 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht,…. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels.

Objective

To provide prevalence estimates of any, no more than 4, or fewer than 2 CMBs in association with amyloid status, APOE ε4 copy number, and age. Design, Setting, and Participants This cross-sectional study used data included in the Amyloid Biomarker Study data pooling initiative (January 1, 2012, to the present [data collection is ongoing]). Data from 15 research and memory clinic studies were pooled and harmonized. Participants included individuals for whom data on age, cognitive status, amyloid status, and presence of CMBs were available. Data were analyzed from October 22, 2023, to April 26, 2024. Main Outcomes and Measures The main outcomes were age, cognitive status, amyloid status and presence, location, and number of CMBs. Presence of amyloid pathology was determined based on 42 amino acid–long form of amyloid-β peptide (Aβ 42 ) levels in cerebrospinal fluid or on amyloid–positron emission tomography. Presence and, in a subset, location (lobar vs deep) and number of CMBs were determined on magnetic resonance imaging (locally with visual rating).

Results

Among 4080 participants included in the analysis, the mean (SD) age was 66.5 (8.9) years, and 2241 (54.9%) were female. A total of 2973 participants had no cognitive impairment (cognitive unimpairment [CU]), and 1107 had mild cognitive impairment (MCI) or AD dementia (ADD). One thousand five hundred and thirteen participants (37.1%) had amyloid pathology, 1368 of 3599 (38.0%) with data available were APOE ε4 carriers, and 648 (15.9%) had CMBs. In the CU group, amyloid pathology and APOE ε4 copy number were not associated with presence of any, no more than 4, or fewer than 2 CMBs but were associated with increased odds of lobar CMBs (odds ratio [OR] for amyloid, 1.42 [95% CI, 1.20-1.69], P < .001; OR for 2 vs 0 alleles, 1.81 [95% CI, 1.19-2.74], P = .006; OR for 1 vs 0 alleles, 1.10 [95% CI, 0.83-1.46], P = .49; and OR for 2 vs 1 allele, 1.64 [95% CI, 0.90-2.97], P = .11; overall P = .02). In the MCI-ADD group, amyloid pathology was associated with presence of any CMBs (OR, 1.51 [95% CI, 1.17-1.96], P = .002), no more than 4 CMBs (OR, 1.44 [95% CI, 1.18-1.82], P = .002), and fewer than 2 CMBs (OR 1.34 [95% CI, 1.03-1.74], P = .03) but not lobar CMBs. APOE ε4 copy number was associated with presence of any (OR for 2 vs 0 alleles, 1.72 [95% CI, 0.88-3.35], P = .11; OR for 1 vs 0 alleles, 0.78 [95% CI, 0.59-1.04], P = .09; and OR for 2 vs 1 allele, 2.20 [95% CI, 1.32-3.67], P = .002; overall P < .001) and no more than 4 CMBs (OR for 2 vs 0 alleles, 1.31 [95% CI, 0.64-2.68], P = .45; OR for 1 vs 0 alleles, 0.75 [95% CI, 0.54-1.04], P = .08; and OR for 2 vs 1 allele, 1.76 [95% CI, 0.97-3.19], P = .06; overall P = .03) but not with fewer than 2 or lobar CMBs. Prevalence estimates of CMBs ranged from 6% at 50 years of age in a non– APOE ε 4 allele carrier with no amyloid pathology and no cognitive impairment to 52% at 90 years of age in an APOE ε 4 homozygote carrier with amyloid pathology and cognitive impairment. Conclusions and Relevance In this cross-sectional study of 4080 participants, prevalence estimates of CMBs were associated with amyloid status, APOE ε4 copy number, and age. CMB prevalence estimates may help inform safety evaluations for antiamyloid clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral HemorrhageAlzheimer DiseaseAmyloid beta-PeptidesHumansFemaleMaleAgedCross-Sectional StudiesBiomarkersAged, 80 and overMiddle AgedApolipoprotein E4Risk FactorsPrevalencePositron-Emission Tomography

Substanzen

Amyloid beta-PeptidesBiomarkersApolipoprotein E4

Autor:innen und Institutionen

  • Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Research and Development, Biogen Inc, Cambridge, Massachusetts.
  • Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.
  • Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
  • Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Förderung

  • NIA NIH HHS

Zitieren

APA

Oomens, J. E., van Gils, V., Vos, S. J. B., Freeze, W. M., Maserejian, N. N., Curiale, G., Gillis, C., Boada, M., van der Flier, W. M., Hort, J., Johnson, S. C., Lleó, A., Ramakers, I. H., Rodrigue, K. M., Sánchez-Juan, P., Sarazin, M., Scarmeas, N., Zetterberg, H., Alcolea, D., …, & BIOFACE Study Group (2025). Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study. JAMA Network Open, 8(1), e2455571. https://doi.org/10.1001/jamanetworkopen.2024.55571

Vancouver

Oomens JE, van Gils V, Vos SJB, Freeze WM, Maserejian NN, Curiale G, et al. Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study. JAMA Network Open. 2025;8(1):e2455571. doi:10.1001/jamanetworkopen.2024.55571

BibTeX
@article{Oomens2025,
  author = {Oomens, Julie E and van Gils, Veerle and Vos, Stephanie J B and Freeze, Whitney M and Maserejian, Nancy N and Curiale, Gioacchino and Gillis, Cai and Boada, Mercè and van der Flier, Wiesje M and Hort, Jakub and Johnson, Sterling C and Lleó, Alberto and Ramakers, Inez H and Rodrigue, Karen M and Sánchez-Juan, Pascual and Sarazin, Marie and Scarmeas, Nikolaos and Zetterberg, Henrik and Alcolea, Daniel and Barkhof, Frederik and Blennow, Kaj and Bottlaender, Michel and den Braber, Anouk and Cerman, Jirí and Drake-Perez, Marta and Fortea, Juan and Handels, Ron and Ingala, Silvia and Jiménez-Bonilla, Julio F and Karavasilis, Stratos and Lagarde, Julien and Legdeur, Nienke and Lorenzini, Luigi and Marquié, Marta and Moonen, Justine E F and Olivieri, Pauline and Orellana, Adelina and Ossenkoppele, Rik and Rivera-Rivera, Leonardo A and Rodríguez-Rodriguez, Eloy and Ruiz Laza, Agustín and Teunissen, Charlotte E and Tijms, Betty M and Velonakis, Giorgos and Verhey, Frans R J and Visser, Pieter Jelle and Jansen, Willemijn J and European Prevention of Alzheimer’s Dementia (EPAD) Consortium, European Prevention of Alzheimer’s Dementia (EPAD) Consortium and Fundació ACE Healthy Brain Initiative (FACEHBI) Study Group, Fundació ACE Healthy Brain Initiative (FACEHBI) Study Group and BIOFACE Study Group, BIOFACE Study Group},
  title = {Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {1},
  pages = {e2455571},
  doi = {10.1001/jamanetworkopen.2024.55571}
}
Kostenlos starten →